Lidia Larrañaga. Qualified person / Regulatory affairs.
Ander Larrañaga. General Manager/ Business Development.
Giuseppe Tomasi Scianó.
In the 1990s, the Basque business group SARRALLE decided to diversify its investments. With the support of a team of researchers from the University of the Basque Country, the determination was made to create a pharmaceutical laboratory focused on the marketing of generics and the development of new medications: thus, LITAPHAR Laboratories was born. This initiative represents cutting-edge research, an unwavering commitment to quality, and an innovative vision in the pharmaceutical field.
In the early 2000s, upon realizing that generics did not meet expectations, the decision was made to sell the primary line of work and focus entirely on the research and development of new products, especially in the gynecological field. We identified the need to innovate in women’s health, making gynecological research our primary challenge.
Today, multiple companies market products developed by LITAPHAR. Our commitment to agility in development is one of our core principles. We possess a dynamic and agile structure, leading a broad network of highly specialized collaborators. This synergy enables us to achieve goals within short time frames and meet our clients’ needs with excellence and efficiency.
A young company, with consolidated knowledge.
In LITAPHAR, our research focuses on advancing new indications that provide therapeutic solutions for diseases associated with women’s health, many of which have yet to be addressed.
Since 2002, we have led research in gynecology and obstetrics, exploring innovative applications with prostaglandin analogs, progesterone receptor antagonists, and selective progesterone receptor modulators to offer cutting-edge treatments:
- Uterine fibroids
- Postpartum hemorrhage
- Dysfunctional uterine bleeding
- Labor induction
- Cervical dilation
- Voluntary pregnancy termination
- Emergency contraception
Additionally, we are pioneers in researching women’s sexual health and quality of life.